Platelet activating factor (PAF) is a potent phospholipid mediator of inflammation that has been gaining increasing attention because of its pathophysiologic effects upon the lung. In particular, PAF stimulates pulmonary hypertension, ventilatory alterations, bronchoconstriction, airway hyperreactivity, and pulmonary inflammatory cell accumulation and edema in a variety of experimental animals and in humans. These observations promote the speculation that this unique phospholipid likely is involved in similar tissue responses during the course of human lung disease. The use of specific PAF antagonists should expand our understanding of these processes and may be useful in treating or preventing PAF-mediated pulmonary disorders in the future.
|Original language||English (US)|
|Journal||Clinics in Chest Medicine|
|Publication status||Published - Jan 1 1989|
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine